61565-36-4

Usage

Explanation

The compound consists of 9 carbon atoms, 7 hydrogen atoms, 1 chlorine atom, 3 oxygen atoms, and 1 sulfur atom.

Explanation

The indene core structure contains a six-membered aromatic ring, with a chlorine atom and a sulfonyl group (-SO2Cl) attached to it.

Explanation

Another way to name the compound, highlighting the presence of a chlorine atom at position 5 of the indene ring and a sulfonyl group attached to the indan ring system.

Explanation

The compound is commonly used as a reagent for introducing sulfonyl groups into various organic molecules.

Explanation

Due to its versatile chemical properties, 1H-Indene-5-sulfonyl chloride, 2,3-dihydro-1-oxois used in the production of various chemicals, including pharmaceuticals, agrochemicals, and fine chemicals.

Explanation

The compound serves as an important intermediate for the synthesis of more complex organic molecules, making it a valuable building block in organic chemistry.

Structure

Six-membered ring with a chlorine atom and a sulfonyl group

Usage

Reagent in organic synthesis

Applications

Production of pharmaceuticals, agrochemicals, and fine chemicals

Importance

Building block in the synthesis of complex organic molecules

Upstream product

• 132630-11-6 5-(benzylthio)-2,3-dihydro-1H-inden-1-one 
• 3470-54-0 5-aminoindan-1-one 
• 34598-49-7 5-Bromo-1-indanone 

Downstream Products

• 83-33-0 inden-1-one 

Relevant academic research and scientific papers

Discovery of Chromane-6-Sulfonamide Derivative as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist

Interleukin-17 (IL-17) is a proinflammatory cytokine that plays a dominant role in inflammation, autoimmunity, and host defense. RORγt is a key transcription factor mediating T helper 17 (Th17) cell differentiation and IL-17 production, which is able to activate CD8+ T cells and elicit antitumor efficacy. A series of sulfonamide derivatives as novel RORγt inverse agonists were designed and synthesized. Using GSK2981278 (phase II) as a starting point, we engineered structural modifications that significantly improved the activity and pharmacokinetic profile. In animal studies, oral administration of compound d3 showed a robust and dose-dependent inhibition of the IL-17A cytokine expression in a mouse imiquimod-induced skin inflammation model. Docking analysis of the binding mode revealed that the compound d3 occupied the active pocket suitably. Thus, compound d3 was selected as a clinical compound for the treatment of Th17-driven autoimmune diseases.

INDANYL COMPOUNDS AS VOLTAGE GATED SODIUM CHANNEL MODULATORS

The invention relates to indanyl compounds, their pharmaceutically acceptable salts thereof, processes for their preparation and pharmaceutical compositions comprising the same for the treatment, management and /or lessening severity of diseases, disorders, syndromes or conditions which are associated with the voltage-gated sodium channels (VGSC). More specifically the present invention provides compounds having the structure of Formula (I).

Synthesis of N-(1-Keto) and N-(1-Hydroxy-5-indansulfonyl)-N'-(4-chlorophenyl)urea, Two Major Metabolites of the Antitumor Agent Sulofenur (LY 186641)

A brief (3-4 step), large-scale synthesis of two major metabolites of the antitumor agent sulofenur was developed.The required intermediate, 1-keto-5-indansulfonamide, was prepared in only two steps, utilizing a novel method for converting an aromatic chl